jumping translocation breakpointGenealiases: HJTB · HSPC222 · PAR · hJT
Q-omics provides the consensus-scored JTB profile across patient tissues and cancer cell-line models. JTB expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, JTB is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, JTB RNA expression shows 20,425 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, BLCA, and ACC as cancer lineages where JTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JTB survival associations across molecular data types. JTB RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JTB RNA expression–survival associations across cancer types. High JTB expression shows unfavorable associations in KIRP, UVM, KICH, ACC, ESCA and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for JTB RNA expression.
This table summarizes JTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for JTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JTB shows higher tumor expression in BLCA, KIRC, LIHC, HNSC, LUAD and COAD. The BLCA box plot shows higher JTB RNA expression in tumor versus normal tissue (log2 FC = +0.932, t-test p < 0.001).
This table shows molecular features associated with JTB in patient tissues and cancer cell lines. In patient samples, JTB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, JTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
